BIAF

What one share of bioAffinity Technologies holds

Services – Commercial Physical and Biological Research

bioAffinity Technologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Sales$1.55
Profit−$4.00
Capex (buildings and equipment)$0.02
Free cash flow−$3.04
Cash and investments$0.36
Debt$0.01
Book value$0.56

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2021—−$70.94———−$176.95
2022$46.01−$54.37$1.47−$28.61—$39.53
2023$27.09−$27.22$0.08−$20.79—$15.50
2024$23.16−$22.37$0.20−$18.17—$5.01
2025$3.58−$8.66$0.04−$5.46—$1.62

Common questions about bioAffinity Technologies

How much does one share of bioAffinity Technologies earn?

Over the last 12 months, bioAffinity Technologies lost $4.00 for each share on $1.55 of sales.

Does bioAffinity Technologies pay a dividend?

bioAffinity Technologies didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is bioAffinity Technologies’s book value per share?

bioAffinity Technologies’s book value is $0.56 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of bioAffinity Technologies have?

Each share of bioAffinity Technologies has $0.36 of cash and investments and $0.01 of debt, as of June 30, 2026.

What is bioAffinity Technologies’s free cash flow per share?

−$3.04 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.

Has bioAffinity Technologies bought back shares?

bioAffinity Technologies’s share count rose about 1830% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.